Pantoloc (Pantoprazole Sodium Sesquihydrate)

Pantoprazole sodium sesquihydrate, the active ingredient in Pantoloc, is a proton pump inhibitor presented as a 40 mg tablet for oral use. It reduces stomach acid production and is used to manage gastro‑reflux and other acid‑related disorders in adults.

GNH USA supplies Pantoloc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoloc is a proton pump inhibitor that acts on conditions related to excess gastric acidity. - Gastro‑esophageal reflux disease (GERD): provides symptomatic relief and promotes healing of erosive esophagitis. - Erosive gastritis and duodenal ulcer disease: supports ulcer healing by maintaining a higher gastric pH. - Zollinger‑Ellison syndrome: controls gastric acid hypersecretion associated with this rare endocrine disorder.

Pantoloc may cause adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually self‑limiting. - Nausea or abdominal discomfort. - Flatulence or bloating. - Constipation. - Dry mouth.

Serious or Rare Side Effects: - Acute interstitial nephritis: inflammation of kidney tissue. - Severe hypersensitivity reactions: including rash, angioedema or anaphylaxis. - Clostridioides difficile‑associated colitis: severe diarrhea with abdominal pain. - Osteoporotic fractures: increased risk with long‑term use. - Low magnesium levels (hypomagnesemia): may cause muscle cramps or cardiac arrhythmia.

When prescribing Pantoloc, clinicians should consider several safety aspects. - Assess renal function: dose adjustment may be required in severe impairment. - Review concomitant medications: potential for interaction with drugs that need gastric acidity. - Monitor for long‑term therapy: consider bone health and magnesium status. - Use caution in pregnancy: only if the potential benefit outweighs risk. - Store below 25°C: keep in the original container, protect from moisture and light.

Pantoloc can affect the absorption or metabolism of several co‑administered drugs.

Major Interactions (Avoid): - Atazanavir or other protease inhibitors: reduced antiviral efficacy. - Clopidogrel: decreased antiplatelet activation.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR values. - Methotrexate: increased systemic exposure. - Digoxin: modest increase in serum concentrations. - Iron salts or ketoconazole: reduced absorption due to higher gastric pH.